Baxter Belgium Manufacturing SA (labeling, secondary packaging and batch release of GLZ and solvent)
UkraineAll drugs from this manufacturer
-
The drug is intended for the treatment and prevention of bleeding in patients with hemophilia B (congenital factor IX deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage nonacog gamma 250 IU ATC: B02BD04
-
The drug is intended for the treatment and prevention of bleeding in patients with hemophilia B (congenital factor IX deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage nonacog gamma 500 IU ATC: B02BD04
-
The drug is intended for the treatment and prevention of bleeding in patients with hemophilia B (congenital factor IX deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage nonacog gamma 1000 IU ATC: B02BD04
-
The drug is intended for the treatment and prevention of bleeding in patients with hemophilia B (congenital factor IX deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage nonacog gamma 2000 IU ATC: B02BD04
-
The drug is indicated for the treatment and prevention of bleeding in patients with hemophilia B (congenital factor IX deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage nonacog gamma 3000 IU ATC: B02BD04